Abstract:Poly(ADP-ribose) polymerases(PARPs) are a large enzyme family which consists of at least 17 members.These enzymes are implicated in multiple cellular processes through catalysis of the addition of ADP-ribose polymers on various acceptor proteins.PARP-1,the most abundant isoform which can be activated by DNA damage,plays an important role in the repair of DNA single strand breaks(SSBs) under normal circumstances.However,PARP-1 can also contribute to resistance after cancer therapy due to its DNA repair activity.Thus PARP inhibitors have been pursued for many years as chemo/radiotherapy sensitizers in cancer treatment.Besides being used in combination,PARP inhibitors may also be applied as monotherapy in some specific cancer types with synthetic lethality as the main mechanism of action.There are currently at least six compounds being investigated in clinical trials,including BSI201,AZD2281,ABT888,MK4827,AG014699,and INO1001.NU1085,developed by the University of Newcastle,has been used as a benchmark of PARP inhibitors due to its potent activity and other good features.We used NU1085 as the lead compound,attempting to find more desirable PARP inhibitors through structural modification.Docking between PARP-1 and the designed molecules showed that introduction of lipid soluble groups at 4′-position might improve the PARP inhibitory activity.In addition,a series of 4-carborsylate derivatives were also designed and synthesized to find novel PARP inhibitors.Twenty-two benzimidazole derivatives were synthesized in all,starting with 3-nitrophthalic anhydride which underwent ring-opening,Hofmann rearrangement,amidation or esterification,and reduction to give diamino compounds.Condensation of the diamino compounds with benzaldehyde or its derivatives afforded the target compounds.All the target compounds were structurally confirmed by 1H-NMR,IR and MS and seventeen compounds were novel ones.The following poly(ADP-ribose) polymerase inhibitory activity assay in vitro showed that most of the target compounds exhibited potent PARP inhibitory activity,and structural modification at 4′-position resulted in increased potency.Compounds Ⅰ2,Ⅱ2,Ⅱ3,Ⅱ8,Ⅱ10 displayed single digit nanomolar inhibition of PARP-1 with IC50=1.5,3.32,2.89,6.42 and 4.26 nmol · L-1,respectively.

Design, Synthesis and Activity of Benzofuran-7-carboxamide Poly(ADP-ribose)-polymerase Inhibitors

Synthesis and evaluation of benzimidazole derivatives as poly(ADP-ribose) polymerase inhibitors

Design, Synthesis, Biological Evaluation and Molecular Docking Study of Novel Urea-Based Benzamide Derivatives As Potent Poly(adp-Ribose) Polymerase-1 (PARP-1) Inhibitors

Discovery of 2-(1-(3-(4-Chloroxyphenyl)-3-oxo- propyl)pyrrolidine-3-yl)-1H-benzo[d]imidazole-4-carboxamide: A Potent Poly(ADP-ribose) Polymerase (PARP) Inhibitor for Treatment of Cancer

Design, Synthesis and Biological Evaluation of Novel 5-Fluoro-1h-benzimidazole-4-carboxamide Derivatives As Potent PARP-1 Inhibitors.

Design, synthesis, and biological evaluation of a series of benzofuran[3,2-<i>d</i>] pyrimidine-4(3<i>H</i>)-one derivatives containing thiosemicarbazone analogs as novel PARP-1 inhibitors

Design, Synthesis and Activity Evaluation of New Phthalazinone PARP Inhibitors.

Structure-Based Pharmacophore Modeling, Virtual Screening, Molecular Docking and Biological Evaluation for Identification of Potential Poly (Adp-Ribose) Polymerase-1 (PARP-1) Inhibitors

Design, synthesis, and biological evaluation of a series of benzofuran[3,2-d]pyrimidine-4(3H)-one derivatives containing thiosemicarbazone analogs as novel PARP-1 inhibitors

Design and Synthesis of Benzo-Spirocyclic Derivatives as Potent PARP-1 Inhibitors

Molecular modeling studies on benzimidazole carboxamide derivatives as PARP-1 inhibitors using 3D-QSAR and docking.

Novel Tricyclic Poly (Adp-Ribose) Polymerase-1/2 Inhibitors with Potent Anticancer Chemopotentiating Activity: Design, Synthesis and Biological Evaluation.

Design, Synthesis and Biological Evaluation of Novel Molecules As Potent PARP-1 Inhibitors.

PARP1: A Promising Target for the Development of PARP1-based Candidates for Anticancer Intervention

Poly(ADP-ribose) Polymerase (Parp)-Based Pharmacophore Model Development and Its Application in Designing Antitumor Inhibitors

Design and Synthesis of Novel Phthalazinone Derivatives As Potent Poly(adp-Ribose)polymerase 1 Inhibitors.

Discovery of Novel Benzamide Derivatives Bearing Benzamidophenyl and Phenylacetamidophenyl Scaffolds As Potential Antitumor Agents Via Targeting PARP-1.

Discovery and SAR Study of 2-(1-propylpiperidin-4-yl)-3h-imidazo[4,5-c]pyridine-7-carboxamide: A Potent Inhibitor of Poly(adp-Ribose) Polymerase-1 (PARP-1) for the Treatment of Cancer.

Synthesis and Biological Evaluation of Piperidyl Benzimidazole Carboxamide Derivatives As Potent PARP-1 Inhibitors and Antitumor Agents

Discovery of the PARP (poly ADP-ribose polymerase) inhibitor 2-(1-(4,4-difluorocyclohexyl)piperidin-4-yl)-1H-benzo[d]imidazole-4-carboxamide for the treatment of cancer.

Design and Activity of Novel Oxadiazole Based Compounds That Target Poly(ADP-ribose) Polymerase